Overall rank by patents
#24,390
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 6 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).
The verdict
GS holds 11 US patents across 6 technology areas, rank #24,390 of 50,000 tracked assignees.
GS Elektromedizinische Geräte G. Stemple Gmbh has been granted 11 US utility patents between 2017 and 2025, placing GS Elektromedizinische Geräte G. Stemple Gmbh at rank #24,390 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.1 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a Foreign Corporation, GS Elektromedizinische Geräte G. Stemple Gmbh is one of the more focused assignees in the PatentsView dataset. By volume, GS sits between Grace Technologies, Inc. (11 patents, rank #24,386) and Guangdong Huarun Paints Co., Ltd (11 patents, rank #24,394) - the closest US assignees by grant volume. The composite Innovation Score of 46.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 9 grants, compared with 2 in the 2015–2019 window, a +350% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. GS Elektromedizinische Geräte G. Stemple Gmbh's 16.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark GS Elektromedizinische Geräte G. Stemple Gmbh against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
GRACE TECHNOLOGIES, INC.
11 patents
GRAPHENE PLATFORM CORPORATION
11 patents
GRI BIO, INC.
11 patents
GRONINGER & CO. GMBH
11 patents
GSC SECRYPT, LLC
11 patents
GSK Consumer Healthcare SARL
11 patents
GT METABOLIC SOLUTIONS, INC.
11 patents
GUANGDONG HUARUN PAINTS CO., LTD
11 patents
GS Elektromedizinische Geräte G. Stemple GmbH
11 patents
What this shows GS holds 11 patents at rank #24,390, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
GS's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
47 Top 20% higher than 80% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 9.1% |
| 2018 | 1 | 9.1% |
| 2020 | 1 | 9.1% |
| 2021 | 1 | 9.1% |
| 2022 | 3 | 27.3% |
| 2023 | 2 | 18.2% |
| 2024 | 1 | 9.1% |
| 2025 | 1 | 9.1% |
Top 6 of 6 technology areas
Overall rank by patents
#24,390
Across all tracked assignees
46.9 out of 100
How to use this portfolio
GS's 11 grants land it in the top 20% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.